Magnetic nanoparticle hyperthermia enhancement of cisplatin chemotherapy cancer treatment

International Journal of Hyperthermia

Volumn 29, Issue 8, 2013, Pages 845-851

  Petryk, Alicia A ^a,b   Giustini, Andrew J ^a,b   Gottesman, Rachel E ^b   Kaufman, Peter A ^b   Hoopes, P Jack ^a,b  

^a DARTMOUTH COLLEGE   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Cisplatin; Cumulative equivalent minutes; Hyperthermia; Iron oxide; Nanoparticle

Indexed keywords

CISPLATIN; HETASTARCH; MAGNETIC NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST ADENOCARCINOMA; CANCER CHEMOTHERAPY; CANCER INHIBITION; FEMALE; HYPERTHERMIC THERAPY; MAGNETIC FIELD; MOUSE; NONHUMAN; RECTAL DRUG ADMINISTRATION; TEMPERATURE; TEMPERATURE MEASUREMENT; THERAPY EFFECT; TUMOR RECURRENCE;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HYPERTHERMIA, INDUCED; MAGNETITE NANOPARTICLES; MICE; MICE, INBRED C3H; TUMOR BURDEN;

EID: 84887908106     PISSN: 02656736     EISSN: 14645157     Source Type: Journal    
DOI: 10.3109/02656736.2013.825014     Document Type: Article

References (29)

1. Barlogie B, Corry PM, Drewinko B. In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum (II) and mitomycin C. Cancer Res 1980;40:1165-8. (Pubitemid 10135826)
2. Herman TS, Teicher BA, Collins LS. Effect of hypoxia and acidosis on the cytotoxicity of four platinum complexes at normal and hyperthermic temperatures. Cancer Res 1988;48:2342-7.
3. Hall EJ. Radiobiology for the radiologist. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2000.
4. van Bree C, Rietbroek R, Schopman E, Kipp J, Bakker P. Local hyperthermia enhances the effect of cis-diamminedichloroplatinum( II) on nonirradiated and preirradiated rat solid tumors. Int J Radiation Oncology Biol Phys 1996;36:135,135-96.
5. Bull JM. An update on the anticancer effects of a combination of chemotherapy and hyperthermia. Cancer Res 1984;44: S4853-6.
6. Hahn GM. Metabolic aspects of the role of hyperthermia in mammalian cell inactivation and their possible relevance to cancer treatment. Cancer Res 1974;34:3117-23.
7. Hildebrandt B, Wust P, Ahlers O, Dieing A, Sreenivasa G, Kerner T, et al. The cellular and molecular basis of hyperthermia. Crit Rev Oncol 2002;43:33-56. (Pubitemid 34722786)
8. Song CW, Park HJ, Lee CK, Griffin R. Implications of increased tumor blood flow and oxygenation caused by mild temperature hyperthermia in tumor treatment. Int J Hyperthermia 2005;21: 761-7. (Pubitemid 41807103)
9. Ausmus PL, Wilke AV, Frazier DL. Effects of hyperthermia on blood flow and cis-diamminedichloroplatinum(II) pharmacokinetics in mammary adenocarcinomas. Cancer Res 1992;52:4965-8.
10. Dudar TE, Jain RK. Differential response of normal and tumor microcirculation to hyperthermia. Cancer Res 1984;44:605-12. (Pubitemid 14187461)
11. Fuertes M, Castilla J, Alonso C, Prez J. Cisplatin biochemical mechanism of action: From cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr Med Chem 2003;10:257-66. (Pubitemid 36131658)
12. Gonzalez VM, Fuertes MA, Alonso C, Perez JM. Is cisplatininduced cell death always produced by apoptosis? Mol Pharmacol 2001;59:657-63. (Pubitemid 32273993)
13. Hartmann JT, Kollmannsberger C, Kanz L, Bokemeyer C. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer 1999;83:866-9.
14. Sooriyaarachchi M, Narendran A, Gailer J. Comparative hydrolysis and plasma protein binding of cisplatin and carboplatin in human plasma in vitro. Metallomics 2011;3:49-55.
15. Meyn RE, Corry PM, Fletcher SE, Demetriades M. Thermal enhancement of DNA damage in mammalian cells treated with cisdiamminedichloroplatinum( II). Cancer Res 1980;40:1136-9. (Pubitemid 10135821)
16. Hettinga J, Konings A, Kampinga H. Reduction of cellular cisplatin resistance by hyperthermia-A review. Int J Hyperthermia 1997; 13:439-57. (Pubitemid 27460146)
17. Van de Vaart P, Van der Vange N, Zoetmulder F, Van Goethem A, Van Tellingen O, ten Bokkel Huinink W, et al. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: Pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer 1998;34:148-54. (Pubitemid 28123393)
18. Wallner KE, DeGregorio MW, Li GC. Hyperthermic potentiation of cis-diamminedichloroplatinum(II) cytotoxicity in Chinese hamster ovary cells resistant to the drug. Cancer Res 1986;46:6242-5. (Pubitemid 17221763)
19. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002;53:615-27. (Pubitemid 34177898)
20. Taylor A, Krupskaya Y, Krämer K, Füssel S, Klingeler R, Büchner B, et al. Cisplatin-loaded carbon-encapsulated iron nanoparticles and their in vitro effects in magnetic fluid hyperthermia. Carbon 2010;48:2327-34.
21. Kettering M, Zorn H, Bremer-Streck S, Oehring H, Zeisberger M, Bergemann C, et al. Characterization of iron oxide nanoparticles adsorbed with cisplatin for biomedical applications. Phys Med Biol 2009;54:5109-21.
22. Lee JS, Rodriguez-Luccioni HL, Méndez J, Sood AK, Lpez-Berestein G, Rinaldi C, et al. Hyperthermia induced by magnetic nanoparticles improves the effectiveness of the anticancer drug cis-diamminedichloroplatinum. J Nanosci Nanotechnol 2011; 11:4153-7.
23. Babincov M, Altanerov V, Altaner C, Bergemann C, Babinec P. In vitro analysis of cisplatin functionalized magnetic nanoparticles in combined cancer chemotherapy and electromagnetic hyperthermia. IEEE Trans Nanobioscience 2008;7:15-19.
24. Hoffman NA, Gollin FF, Clifton KH. Acquired radioresistance of transplanted mammary adenocarcinoma in inbred mice after serial irradiation. Radiology 1967;88:568-75.
25. Cohn NK, Clifton KH. Aspects of the biology and radiation response of cloned C3H mouse mammary carcinoma cells in vitro and in vivo. Eur J Cancer 1971;7:505-14.
26. Grüttner C, Müller K, Teller J, Westphal F, Foreman A, Ivkov R. Synthesis and antibody conjugation of magnetic nanoparticles with improved specific power absorption rates for alternating magnetic field cancer therapy. J Magn Magn Mater 2007;311:181-6. (Pubitemid 46401005)
27. micromod Partikeltechnologie, Rostock, Germany. Functionalized Micro-and Nanoparticles, product details (accessed 2013). http://www.micromod.de/en/ functionalized-micro-and-nanoparticles-1.html.
28. Fluxtrol Center for Induction Technology, Auburn Hills, MI. Ferrotron 559H, product details, 2010 (accessed 2013). http://fluxtrol.com/products/ product-types/ferrotron-559h/.
29. Dewhirst MW, Viglianti BL, Lora-Michiels M, Hanson M, Hoopes PJ. Basic principles of thermal dosimetry and thermal thresholds for tissue damage from hyperthermia. Int J Hyperthermia 2003;19: 267-94. (Pubitemid 36740799)